Stockscreener 앱 받기
3.97
2.34%
-0.095
시간 외 거래:
3.97
전일 마감가:
$4.065
열려 있는:
$4.05
하루 거래량:
798
Relative Volume:
0.06
시가총액:
$142.32M
수익:
-
순이익/손실:
$-25.50M
주가수익비율:
-5.1558
EPS:
-0.77
순현금흐름:
$-30.10M
1주 성능:
+2.58%
1개월 성능:
-0.87%
6개월 성능:
+26.03%
1년 성능:
+42.48%
1일 변동 폭
$3.97
$4.09
1주일 범위
$3.8173
$4.09
52주 변동 폭
$2.20
$4.48
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
EPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
3.97 | 138.74M | 0 | -25.50M | -30.10M | -0.77 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-21 | 개시 | Craig Hallum | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
(EPRX) Advanced Equity Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Strengthens Governance with Board Elections and Strategic Approvals - TipRanks
Why Broadcom Stock Blew Past the Market on Monday - The Globe and Mail
Why Meta Platforms Stock Soared on AI News Today - The Globe and Mail
Hogs Close Mixed on Monday - The Globe and Mail
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - GlobeNewswire
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - GlobeNewswire Inc.
Stocks in play: Ares Strategic Mining Inc - The Globe and Mail
Should You Buy Paylocity Stock Despite its 7% Dip in 3 Months? - The Globe and Mail
Most Anticipated Earnings this Week – Week of June 2, 2025 - The Globe and Mail
E3 Lithium Provides Progress Update for the Demonstration Facility - The Globe and Mail
(EPRX.WT.A) Stock Market Analysis - news.stocktradersdaily.com
(EPRX) Investment Strategy and Analysis (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Equity Market Report - news.stocktradersdaily.com
2 Top Stocks to Buy With Less Than $100 - The Globe and Mail
(EPRX) Market Performance Analysis (EPRX:CA) - news.stocktradersdaily.com
Definity Financial Corporation Announces Increased Size of Previously Announced Private Placements of Common Shares to $385 million - The Globe and Mail
Should You Buy High-Yield Enterprise Products Partners While It's Below $36? - The Globe and Mail
(EPRX.WT.A) Technical Patterns and Signals - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Trading Down 0% – Here’s What Happened - Defense World
Travel + Leisure Up 10% in a Month: Hold Steady or Lock in Gains? - The Globe and Mail
(EPRX) Strategic Market Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc - Stockhouse
(EPRX) Long Term Investment Analysis (EPRX:CA) - news.stocktradersdaily.com
Long Term Trading Analysis for (EPRX.WT.A) - news.stocktradersdaily.com
“Bear-Pit Session” Highlights Peterson Capital’s Canada Growth Conference in Montreal - The Globe and Mail
11,613 Shares in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Acquired by Raymond James Financial Inc. - Defense World
(EPRX.WT.A) Comprehensive Trading Strategy Report - news.stocktradersdaily.com
Trading (EPRX) With Integrated Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Raymond James Sticks to Its Buy Rating for Eupraxia Pharmaceuticals (EPRX) - The Globe and Mail
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - The Globe and Mail
Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Wednesday - Defense World
(EPRX.WT.A) Trading Strategy and Analysis - news.stocktradersdaily.com
Eupraxia Pharmaceuticals to Host Virtual KOL Event to - GlobeNewswire
DDOG Q1 Earnings Call: Growth in Large Deals, AI Adoption, and Platform Expansion Drive Outlook - The Globe and Mail
Eupraxia Pharmaceuticals to Host Virtual Event on EoE Treatment Study - TipRanks
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 - GlobeNewswire
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results - Stock Titan
Eupraxia Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
(EPRX.WT.A) Strategic Equity Report - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - ADVFN
Eupraxia Pharmaceuticals Inc. - MENAFN.com
Stocks In Play: Eupraxia Pharmaceuticals Inc. By Baystreet.ca - Investing.com Canada
Aptose Biosciences Inc. - Baystreet.ca
Stocks in play: Eupraxia Pharmaceuticals Inc. - The Globe and Mail
Eupraxia Pharmaceuticals Reports Positive Nine-Month Outcomes in EoE Trial - TipRanks
Eupraxia Pharma Reports Positive 9-month Data From RESOLVE Phase 1b/2a Study - Nasdaq
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI - GlobeNewswire
When the Price of (EPRX) Talks, People Listen (EPRX:CA) - news.stocktradersdaily.com
Breakthrough: New EoE Drug Shows Unprecedented 9-Month DurationCould Transform Treatment Landscape - Stock Titan
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 - Seeking Alpha
Eupraxia Pharmaceuticals Inc (EPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.54%
자본화:
|
볼륨(24시간):